335 related articles for article (PubMed ID: 19407006)
1. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.
Jin Y; Arita M; Zhang Q; Saban DR; Chauhan SK; Chiang N; Serhan CN; Dana R
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4743-52. PubMed ID: 19407006
[TBL] [Abstract][Full Text] [Related]
2. Frontline Science: Aspirin-triggered resolvin D1 controls herpes simplex virus-induced corneal immunopathology.
Rajasagi NK; Bhela S; Varanasi SK; Rouse BT
J Leukoc Biol; 2017 Nov; 102(5):1159-1171. PubMed ID: 28584076
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
4. Resolvin D1 and E1 promote resolution of inflammation in rat cardiac fibroblast in vitro.
Salas-Hernández A; Espinoza-Pérez C; Vivar R; Espitia-Corredor J; Lillo J; Parra-Flores P; Sánchez-Ferrer CF; Peiró C; Díaz-Araya G
Mol Biol Rep; 2021 Jan; 48(1):57-66. PubMed ID: 33459958
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of resolvin D1 and resolvin E1 on cementoblast function.
Bozkurt SB; Hakki SS; Kantarci A
J Periodontol; 2023 Nov; 94(11):1351-1362. PubMed ID: 37322861
[TBL] [Abstract][Full Text] [Related]
6. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist.
Lu P; Li L; Liu G; Zhang X; Mukaida N
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4761-8. PubMed ID: 19458323
[TBL] [Abstract][Full Text] [Related]
7. Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse.
Harrison JL; Rowe RK; Ellis TW; Yee NS; O'Hara BF; Adelson PD; Lifshitz J
Brain Behav Immun; 2015 Jul; 47():131-40. PubMed ID: 25585137
[TBL] [Abstract][Full Text] [Related]
8. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice.
Bento AF; Claudino RF; Dutra RC; Marcon R; Calixto JB
J Immunol; 2011 Aug; 187(4):1957-69. PubMed ID: 21724996
[TBL] [Abstract][Full Text] [Related]
9. Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils.
Qiu FH; Devchand PR; Wada K; Serhan CN
FASEB J; 2001 Dec; 15(14):2736-8. PubMed ID: 11687510
[TBL] [Abstract][Full Text] [Related]
10. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation.
Motwani MP; Colas RA; George MJ; Flint JD; Dalli J; Richard-Loendt A; De Maeyer RP; Serhan CN; Gilroy DW
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563331
[TBL] [Abstract][Full Text] [Related]
11. Critical role of TNF-α-induced macrophage VEGF and iNOS production in the experimental corneal neovascularization.
Lu P; Li L; Liu G; Baba T; Ishida Y; Nosaka M; Kondo T; Zhang X; Mukaida N
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3516-26. PubMed ID: 22570350
[TBL] [Abstract][Full Text] [Related]
12. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions.
Tian H; Lu Y; Sherwood AM; Hongqian D; Hong S
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3613-20. PubMed ID: 19443724
[TBL] [Abstract][Full Text] [Related]
13. Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease.
Kantarci A; Aytan N; Palaska I; Stephens D; Crabtree L; Benincasa C; Jenkins BG; Carreras I; Dedeoglu A
Exp Neurol; 2018 Feb; 300():111-120. PubMed ID: 29126887
[TBL] [Abstract][Full Text] [Related]
14. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation.
Weiss GA; Troxler H; Klinke G; Rogler D; Braegger C; Hersberger M
Lipids Health Dis; 2013 Jun; 12():89. PubMed ID: 23767972
[TBL] [Abstract][Full Text] [Related]
15. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions.
Xu ZZ; Zhang L; Liu T; Park JY; Berta T; Yang R; Serhan CN; Ji RR
Nat Med; 2010 May; 16(5):592-7, 1p following 597. PubMed ID: 20383154
[TBL] [Abstract][Full Text] [Related]
16. Resolvin D1 and E1 promote resolution of inflammation in microglial cells in vitro.
Rey C; Nadjar A; Buaud B; Vaysse C; Aubert A; Pallet V; Layé S; Joffre C
Brain Behav Immun; 2016 Jul; 55():249-259. PubMed ID: 26718448
[TBL] [Abstract][Full Text] [Related]
17. Low levels of pro-resolving lipid mediators lipoxin-A4, resolvin-D1 and resolvin-E1 in patients with rheumatoid arthritis.
Özgül Özdemir RB; Soysal Gündüz Ö; Özdemir AT; Akgül Ö
Immunol Lett; 2020 Nov; 227():34-40. PubMed ID: 32818598
[TBL] [Abstract][Full Text] [Related]
18. Interleukin (IL)-17A Promotes Angiogenesis in an Experimental Corneal Neovascularization Model.
Liu G; Wu H; Lu P; Zhang X
Curr Eye Res; 2017 Mar; 42(3):368-379. PubMed ID: 27419340
[TBL] [Abstract][Full Text] [Related]
19. Resolvin E1 Inhibits Corneal Allograft Rejection in High-Risk Corneal Transplantation.
Wang H; Zhao Q; Luo D; Yin Y; Li T; Zhao M
Invest Ophthalmol Vis Sci; 2018 Aug; 59(10):3911-3919. PubMed ID: 30073362
[TBL] [Abstract][Full Text] [Related]
20. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
